SIRS Therapeutics UG
Latest round
- Seed
Last raised
- Apr 2020
Total raised
- Undisclosed
Investors
- 1
About SIRS Therapeutics UG
Founded in 2020 and based in Munich, Germany, SIRS Therapeutics UG develops and provides FX06, a 28 amino acid peptide from human fibrin that reduces leukocyte extravasation and preserves the endothelial barrier. The company focuses to treat patients with Respiratory Distress Syndrome(ARDS), Systemic Inflammatory Response Syndrome(SIRS), and COVID-19 patients.
Who invested in SIRS Therapeutics UG
1 investor across 1 round
See all investors in SIRS Therapeutics UG
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Apr 15, 2020
Amount
Undisclosed
Investors
Questions about SIRS Therapeutics UG
Who invested in SIRS Therapeutics UG?
SIRS Therapeutics UG has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has SIRS Therapeutics UG raised?
SIRS Therapeutics UG has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did SIRS Therapeutics UG last raise money?
SIRS Therapeutics UG's most recent round on record is a Seed, in Apr 2020.
What does SIRS Therapeutics UG do?
Founded in 2020 and based in Munich, Germany, SIRS Therapeutics UG develops and provides FX06, a 28 amino acid peptide from human fibrin that reduces leukocyte extravasation and preserves the endothelial barrier.
Where is SIRS Therapeutics UG headquartered?
SIRS Therapeutics UG is headquartered in Munich, Germany.
Which VCs invest in companies like SIRS Therapeutics UG?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at SIRS Therapeutics UG's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like SIRS Therapeutics UG? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.